J. Walczak

Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.

S. Litwin, L. Weiner, P. O'dwyer, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen

S. Litwin, L. Weiner, P. O'dwyer, 2005, Cancer Immunology, Immunotherapy.

Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.

R. Ozols, P. O'dwyer, D. Martin, 1991, Journal of the National Cancer Institute.

Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer

R. Ozols, P. O'dwyer, P. Flynn, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic study of trimetrexate in combination with cisplatin.

S. Litwin, P. O'dwyer, G. Hudes, 1991, Cancer research.

Phase II study of weekly 5-fluorouracil, cisplatin and vinblastine in advanced non-small cell lung cancer.

S. Litwin, P. O'dwyer, C. Langer, 1991, European journal of cancer.

Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.

S. Litwin, P. O'dwyer, F. LaCreta, 1993, British Journal of Cancer.

Phase I and pharmacokinetic study of the novel platinum analogue CI-973 on a 5-daily dose schedule.

P. O'dwyer, G. Hudes, R. Schilder, 1992, Cancer research.

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.

R. Ozols, P. O'dwyer, G. Hudes, 1994, Cancer research.